Research studies, summarized and reviewed by Dr. Benjamin Caplan, MD¹ (Page 10)

Clinicians should consider the potential benefits of cannabinoids for improving sleep in patients with chronic neuropathic pain, while remaining cautious about the limited evidence for pain relief.

While purified CBD is generally well-tolerated in clinical trials, the widespread availability of unregulated CBD-infused foods presents safety risks due to unpredictable dosing, lack of extract standardization, and pronounced increases in bioavailability when consumed with dietary fats. Integrative clinicians should counsel patients on the variability and lack of federal safety oversight in commercial CBD food products, keeping potential drug-drug interactions and elevated liver enzyme risks in mind.

While cannabidiol (CBD) demonstrates a favorable safety profile and preliminary signals of efficacy in psychosis and anxiety, there is currently inadequate high-quality evidence to support its use for any psychiatric disorder. Clinicians must advise patients regarding the lack of product regulation, potential for significant CYP450 drug-drug interactions (especially affecting liver transaminases), and the risk of unlabelled THC contamination in commercial formulations.

Clinicians should consider the use of cannabis and cannabinoids as part of a comprehensive treatment plan for cancer patients, focusing on symptom management and patient quality of life.

While cannabis use does not show a significant increase in adverse cardiovascular events, clinicians should remain cautious and consider individual patient factors when discussing cannabis use.

Clinicians should be cautious when prescribing cannabinoid-based medicines to older adults due to the limited data on adverse events. Monitoring for potential adverse effects is essential.

Clinicians should consider the potential role of endocannabinoids in exercise-induced euphoria, but further research is needed to establish definitive links and mechanisms.

This systematic review and meta-analysis demonstrates that standard personality traits do not reliably predict placebo responsiveness, challenging the clinical assumption of a 'placebo personality'. Clinicians and researchers should look to situational, contextual, learning-based, or neurobiological factors rather than baseline personality when assessing variability in patient response to inert treatments or therapies.

The study highlights the importance of understanding the relationship between gene and protein expression for the CB1 receptor, which may inform future drug development strategies.

Clinicians should consider the varying levels of evidence regarding the efficacy and safety of cannabis and cannabinoids when making treatment decisions. Systematic reviews can provide valuable insights into the credibility of these associations.